SABS
SAB Biotherapeutics Inc
$
2.150
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.210
Open
2.180
VWAP
2.15
Vol
76.50K
Mkt Cap
22.38M
Low
2.090
Amount
164.70K
EV/EBITDA(TTM)
--
Total Shares
9.23M
EV
20.12M
EV/OCF(TTM)
--
P/S(TTM)
174.84
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
100.00K
-62%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for SAB Biotherapeutics, Inc. (SABS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 16.22%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+16.22%
In Past 3 Month
3 Analyst Rating
434.88% Upside
Wall Street analysts forecast SABS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SABS is 11.50 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
434.88% Upside
Current: 2.150
Low
9.00
Averages
11.50
High
14.00
434.88% Upside
Current: 2.150
Low
9.00
Averages
11.50
High
14.00
Chardan
Buy
downgrade
$20 -> $12
2025-08-08
Reason
Chardan
Price Target
$20 -> $12
2025-08-08
downgrade
Buy
Reason
Chardan lowered the firm's price target on SAB Biotherapeutics to $12 from $20 and keeps a Buy rating on the shares after the company reported Q2 results. A recent financing will fund the potentially pivotal Phase IIb SAFEGUARD trial of SAB-142 in type I diabetes, notes the analyst, who cites dilution from the fundraising for the company's lowered target.
H.C. Wainwright
initiated
$10
2025-05-14
Reason
H.C. Wainwright
Price Target
$10
2025-05-14
initiated
Reason
H.C. Wainwright assumed coverage of SAB Biotherapeutics with a Buy rating and $10 price target. Following a positive topline data readout in healthy volunteers that showcased sustained immunomodulation and a clean safety profile, SAB's human anti-thymocyte immunoglobulin, SAB-142, is positioning itself as a potential new immunotherapy to prevent and control the progression of type 1 diabetes, the analyst tells investors in a research note.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$6
2025-04-01
Reason
HC Wainwright & Co.
Edward White
Price Target
$6
2025-04-01
Reiterates
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$25 → $20
2025-04-01
Reason
Chardan Capital
Keay Nakae
Price Target
$25 → $20
2025-04-01
Maintains
Strong Buy
Reason
Chardan analyst Keay Nakae lowered the firm's price target on SAB Biotherapeutics to $20 from $25 and keeps a Buy rating on the shares after the company reported its Q4 and full year results. The company remains on track to initiate the Phase 2 SAFEGUARD clinical study to evaluate SAB-142, notes the analyst, who lowered the firm's price target to reflect a higher projected future share count as modeled future capital raises, including one in Q2, are expected to be more dilutive due to the current share price.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$6
2025-01-29
Reason
HC Wainwright & Co.
Edward White
Price Target
$6
2025-01-29
Reiterates
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$25
2025-01-29
Reason
Chardan Capital
Keay Nakae
Price Target
$25
2025-01-29
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for SAB Biotherapeutics Inc (SABS.O) is -3.99, compared to its 5-year average forward P/E of -9.70. For a more detailed relative valuation and DCF analysis to assess SAB Biotherapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.70
Current PE
-3.99
Overvalued PE
6.07
Undervalued PE
-25.47
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
48.52
Current PS
0.00
Overvalued PS
145.00
Undervalued PS
-47.95
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
-4.58%
-9.67M
Operating Profit
FY2025Q2
YoY :
+37.88%
-10.11M
Net Income after Tax
FY2025Q2
YoY :
+37.97%
-1.09
EPS - Diluted
FY2025Q2
YoY :
-7.96%
-7.15M
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
+1903.51%
-26.97K
FCF Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 10058566.67% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SABS News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
07:43:00
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year
2025-07-21 (ET)
2025-07-21
07:38:57
SAB Biotherapeutics announces oversubscribed $175M private placement
2025-05-09 (ET)
2025-05-09
09:03:28
SAB Biotherapeutics reports Q1 net loss $5.2M vs $5M last year
Sign Up For More Events
Sign Up For More Events
News
4.0
07-22BenzingaHC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $9
8.5
07-21NewsfilterSAB BIO Announces Oversubscribed $175 Million Private Placement
9.5
05-09NewsfilterSAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
Sign Up For More News
People Also Watch
NTIP
Network-1 Technologies Inc
1.415
USD
-0.35%
APWC
Asia Pacific Wire & Cable Corporation Ltd
1.710
USD
+0.59%
NMTC
NeuroOne Medical Technologies Corp
0.860
USD
+8.04%
ONMD
Onemednet Corp
0.480
USD
+2.56%
ECDA
ECD Automotive Design Inc
0.151
USD
-10.13%
GLE
Global Engine Group Holding Ltd
0.735
USD
-13.53%
BATL
Battalion Oil Corp
1.233
USD
-3.67%
FTHM
Fathom Holdings Inc
1.300
USD
-9.72%
FTEK
Fuel Tech Inc
3.000
USD
-1.64%
MLEC
Moolec Science SA
2.690
USD
+1.47%
FAQ
What is SAB Biotherapeutics Inc (SABS) stock price today?
The current price of SABS is 2.15 USD — it has decreased -0.46 % in the last trading day.
What is SAB Biotherapeutics Inc (SABS)'s business?
What is the price predicton of SABS Stock?
What is SAB Biotherapeutics Inc (SABS)'s revenue for the last quarter?
What is SAB Biotherapeutics Inc (SABS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for SAB Biotherapeutics Inc (SABS)'s fundamentals?
How many employees does SAB Biotherapeutics Inc (SABS). have?